Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center

  • Jansaka, Natpat (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Faculty of Medicine, Chiang Mai University) ;
  • Suprasert, Prapaporn (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Faculty of Medicine, Chiang Mai University)
  • Published : 2015.01.22


To assess survival outcomes in a retrospective study, recurrent epithelial ovarian cancer patients were divided into three groups according to the platinum free interval as follows: platinum refractory that included the patients with tumor progression during treatment; platinum resistant and platinum sensitive that included the patients with tumor progression less than or more than six months, respectively. Clinical data for tumor progression in epithelial ovarian cancer patients treated at Chiang Mai University Hospital between January, 2006 and December, 2010 were reviewed. Thirty-nine patients were in the platinum refractory group while 27 were in the platinum resistant group and 75 in the platinum sensitive group. The mean age, the parity, the administration of neoadjuvant chemotherapy and the serous type did not significantly different across groups while the mean total number of chemotherapy regimens, the early stage patients, the patients with complete surgery and the surviving patients were significant more frequent in the platinum sensitive group. Regarding subsequent treatment after tumor recurrence, 87.2% underwent chemotherapy. With the median follow up time at 29 months, the median overall survival rates were 20 months, 14 months and 42 months in platinum refractory, platinum resistant and platinum sensitive groups, respectively (p<0.001). In addition, when the platinum sensitive patients developed the next episode of tumor progression, the median progression free interval time was only three to four months. In conclusion, the outcomes for platinum refractory the and platinum resistant groups was poorer than the platinum sensitive group. However, subsequent progression in the platinum sensitive group was also associated with a poor outcome.


  1. Barlin JN, Yu C, Hill EK, et al (2012). Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol, 125, 25-30.
  2. Ciucci A, Zannoni GF, Travaglia D, et al (2014). Prognostic significance of the estrogen receptor beta ($ER{\beta}$) isoforms $ER{\beta}1$, $ER{\beta}2$, and $ER{\beta}5$ in advanced serous ovarian cancer. Gynecol Oncol, 132, 351-9.
  3. Chien J, Kuang R, Landen C, et al (2013). Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol, 24, 243-51.
  4. Foley OW, Rauh-Hain JA, del Carmen MG (2013). Recurrent epithelial ovarian cancer: an update on treatment. Oncology, 27, 288-94.
  5. Gonzalez-Martin A (2013). Update on randomized trials on recurrent disease. Ann Oncol, 24, 1-5.
  6. Harter P, Heitz F, du Bois A (2012). Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep, 14, 539-43.
  7. Raja FA, Counsell N, Colombo N, et al (2013). Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol, 24, 3028-34.
  8. Suprasert P, Manopunya M, Cheewakriangkrai C (2014). Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience. Asian Pac J Cancer Prev, 15, 1145-8.
  9. Suprasert P, Chalapati W (2013). Detection of recurrence in a surveillance program for epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 7193-6.
  10. Suprasert P, Cheewakriangkrai C, Manopunya M (2012). Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma. Asian Pac J Cancer Prev, 13, 517-20.
  11. Thigpen T (2012). A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol, 55, 114-30.